Navigation Links
Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis

liefs are based on preliminary information and management assumptions. Specifically, no assurances can be made with respect to: the initiation, timing and results of a 6-month nasal toxicology study; the importance and potential differentiating quality of the product candidate's taste profile; and the timing or outcome of the Company's meetings with the FDA regarding the epinastine nasal spray clinical program. Such forward-looking statements are subject to a wide range of risks and uncertainties that could cause results to differ in material respects, including those relating to additional clinical trials or discussions with the FDA regarding the epinastine nasal spray program, the amount of net sales of Restasis recorded by Allergan in 2007, the Company's 2007 financial results, including without limitation aggregate revenue, aggregate expenses, research and development expenses, selling and marketing expenses, general and administrative expenses, as well as the impact of the anticipated AzaSite launch, including without limitation headcount changes, related stock-based compensation expense changes, a draw on the Company's existing debt facility, the timing of any revised guidance, the timing and success of any additional capital raising activities, product development, revenue, expense and earnings expectations, the seasonality of Elestat, intellectual property rights, adverse litigation developments, adverse developments in the U.S. Securities and Exchange Commission (SEC) investigation, competitive products, results and timing of clinical trials, success of marketing efforts, the need for additional research and testing, delays in manufacturing, funding, and the timing and content of decisions made by regulatory authorities, including the U.S. Food and Drug Administration. Further information regarding factors that could affect Inspire's results is included in Inspire's filings with the SEC. Inspire undertakes no obligation to publicly release the results of an
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Inspire Announces Presentations at Two European Scientific Conferences
3. Inspire Announces Presentations at 2007 Association for Research in Vision and Ophthalmology Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:4/21/2015)... April 21, 2015 The saturated European market ... the rising incidence of preterm births. This trend is ... unit (NICU) devices but also skilled and trained professionals ... Frost & Sullivan, Analysis of the Western European Infant ... of $151.5 million in 2014 and estimates this to ...
(Date:4/20/2015)... WASHINGTON , April 21, 2015  Following is ... Bureau: LIFESAVING MEDICINE ... world,s most important medicines — insulin —became available for ... of millions of people suffering from diabetes. Insulin is ... in the processing of carbohydrates in the human body. ...
(Date:4/20/2015)... YORK , April 20, 2015 This report ... by the following Segments: Toxicology Testing (In-Vivo, & In-Vitro), and ... US, Canada , Japan ... , and Rest of World. Annual estimates and forecasts are ... historic analysis is provided for these markets. Market data and ...
Breaking Medicine Technology:Rising Numbers of Preterm Births Stoke Demand for Infant Care Solutions in Europe 2Rising Numbers of Preterm Births Stoke Demand for Infant Care Solutions in Europe 3U.S. Census Bureau Daily Feature for April 21 2World ADME-Toxicology Testing Industry 2World ADME-Toxicology Testing Industry 3World ADME-Toxicology Testing Industry 4World ADME-Toxicology Testing Industry 5World ADME-Toxicology Testing Industry 6World ADME-Toxicology Testing Industry 7World ADME-Toxicology Testing Industry 8World ADME-Toxicology Testing Industry 9World ADME-Toxicology Testing Industry 10World ADME-Toxicology Testing Industry 11World ADME-Toxicology Testing Industry 12World ADME-Toxicology Testing Industry 13World ADME-Toxicology Testing Industry 14World ADME-Toxicology Testing Industry 15World ADME-Toxicology Testing Industry 16World ADME-Toxicology Testing Industry 17World ADME-Toxicology Testing Industry 18World ADME-Toxicology Testing Industry 19
(Date:4/21/2015)... Renewable energy, sustainable living, the greening ... Earth Day topics USM Studios ’ programming covers ... the affect of climate change on the planet, the ... touching on the environmental concerns affecting the nation and ... sustainable lifestyles, clean air options, and much more when ...
(Date:4/21/2015)... On Saturday, May 2nd, 2015, board certified ophthalmologist ... from Georgia Eye Physicians and Surgeons will ... held in Piedmont Park by the Lupus Foundation of ... largest LFA-sponsored walk in the nation, hosting more than ... awareness for lupus, an unpredictable and potentially fatal autoimmune ...
(Date:4/21/2015)... April 21, 2015 Invictus Medical ... prestigious Illinois university for a second innovative technology ... more conducive to newborn infants’ cognitive development. , ... NICU problems we have identified through extensive interviews ... said George Hutchinson, Invictus Medical’s Chief Technology Officer. ...
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 “The warm ... SunGrubbies.com. “Doesn’t every mother want to look younger than her ... is the first line of defense. Signs of ... are the evidence of too much time spent in the ... only reason to cover up. The dangers of UV ...
(Date:4/20/2015)... Heritage Woods of Centralia, a Gardant ... and Dine-and-Dash Spaghetti Dinner from 4 p.m. to 6 ... located in Centralia, Illinois, houses senior living apartments, affordable ... 55 and older. , Guests are invited to tour ... options for seniors. After the tours, they can take ...
Breaking Medicine News(10 mins):Health News:USM Studios’ Programming Focuses on the Environment 2Health News:9th Annual Walk to End Lupus Now 2Health News:9th Annual Walk to End Lupus Now 3Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2
... Mich. Want to keep your boss happy? Smile at ... like you mean it. A new study led by ... fake smile throughout the day worsen their mood and withdraw ... result of cultivating positive thoughts such as a tropical ...
... Use of the blood clot-inhibiting medication tifacogin does not ... pneumonia (sCAP), according to a study conducted by researchers ... The drug had shown some potential benefit in the ... The findings were published online ahead of the ...
... -- The portion of the brain responsible for visual reading ... by researchers from the Hebrew University of Jerusalem and France. ... read words in Braille show activity in precisely the same ... read. The findings challenge the textbook notion that the brain ...
... on the treatment of liver cancer, according to a ... used molecular-sized bubbles filled with chemotherapy drugs to prevent ... and mice. Researchers evaluated the use of molecular-sized ... agent. Ceramide is a lipid molecule naturally present in ...
... (MGH) researchers to shield the ovaries of female mammals ... passed an important milestone. A collaborative study with ... online in the journal Fertility and Sterility, reports that ... called FTY720 preserved the fertility of female rhesus monkeys ...
... Radiologists who interpret a high volume of mammograms may ... suspicious lesions are not malignant, according to a new study ... Radiology . "Contrary to our expectations, we observed no ... author, Diana S.M. Buist, Ph.D., M.P.H., senior investigator at the ...
Cached Medicine News:Health News:Study: For a better workday, smile like you mean it 2Health News:Anti-clotting agent does not improve outcomes of patients with severe pneumonia 2Health News:Anti-clotting agent does not improve outcomes of patients with severe pneumonia 3Health News:Brain doesn't need vision at all in order to 'read' material 2Health News:Brain doesn't need vision at all in order to 'read' material 3Health News:Nanotechnology may lead to new treatment of liver cancer 2Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 2Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 3Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 4Health News:Higher volume reduces false positives in screening mammography 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: